| Literature DB >> 33305208 |
Mélanie Suppan1, Gleicy Barcelos1, Stéphane Luise1, John Diaper1, Angela Frei2, Christoph Ellenberger1, Dionysios Adamopoulos2, Stéphane Noble2,3, Marc Licker1,3.
Abstract
BACKGROUND: Transcatheter aortic valve implantation (TAVI) represents an effective therapeutic procedure, particularly in patients with severe aortic stenosis. We hypothesized that the decreased afterload induced by TAVI would improve exercise capacity by enhancing oxygen uptake in working muscles.Entities:
Year: 2020 PMID: 33305208 PMCID: PMC7710946 DOI: 10.1016/j.cjco.2020.06.005
Source DB: PubMed Journal: CJC Open ISSN: 2589-790X
Figure 1Flow chart. ∗ < 25% exercise load increase (post- vs pre- transcatheter aortic valve implantation).
Patients and procedural characteristics based on Valve Academic Research Consortium-2 recommendations
| Characteristic | All (N = 30) | Low-responders∗ (n = 11) | High-responders (n = 19) | P |
|---|---|---|---|---|
| Age (y) | 86 (79–89) | 86 (79–88) | 85 (81–90) | 0.880 |
| BMI (kg/m2) | 26.6 (22.5–32.0) | 25.0 (20.9–29.7) | 27.4 (22.5–32.4) | 0.464 |
| Sex (female) | 15 (50) | 4 (36) | 11 (58) | 0.264 |
| Ischemic heart disease | 18 (60) | 5 (45) | 13 (68) | 0.224 |
| Congestive heart failure | 7 (23) | 3 (27) | 4 (21) | 0.703 |
| Hypertension | 23 (77) | 8 (73) | 15 (79) | 0.703 |
| Diabetes mellitus | 7 (23) | 4 (36) | 3 (16) | 0.207 |
| Chronic renal failure | 14 (47) | 7 (64) | 7 (34) | 0.163 |
| Cerebral vascular disease | 7 (23) | 3 (27) | 4 (21) | 0.703 |
| Peripheral vascular disease | 5 (17) | 3 (27) | 2 (11) | 0.244 |
| Chronic obstructive pulmonary disease | 6 (20) | 2 (18) | 4 (21) | 0.852 |
| STS risk score | 6.0 (3.3–7.6) | 6.1 (4.0–13.4) | 5.8 (3.2–6.5) | 0.254 |
| EuroScore | 7.9 (5.3–14.4) | 7.3 (5.2–16.1) | 8.5 (5.3–14.4) | 0.846 |
| Left ventricular ejection fraction (%) | 65 (55–65) | 65 (55–65) | 65 (53–65) | 0.852 |
| Hemoglobin (g/l) | 128 (117–138) | 127 (115–140) | 128 (117–132) | 0.590 |
| Creatinine (μmol/l) | 86 (78–104) | 97 (77–113) | 84 (78–101) | 0.344 |
| Frailty parameters | ||||
| Gait speed (m/s) | 0.8 (0.7–0.9) | 0.8 (0.7–0.9) | 0.7 (0.5–1.1) | 0.463 |
| Grip strength (kg) | 24 (21–31) | 22 (21–28) | 26 (20–33) | 0.355 |
| Unintentional weight loss | 5 (17) | 2 (18) | 3 (16) | 0.868 |
| Recent fall | 14 (47) | 5 (46) | 9 (47) | 0.921 |
| Poor mobility | 4 (13) | 1 (9) | 3 (16) | 0.673 |
| Serum albumin (g/l) | 43 (40–43) | 41 (36–44) | 43 (40–43) | 0.632 |
| MMSE | 29 (26–30) | 29 (28–30) | 27 (25–30) | 0.150 |
| Procedural aspects | ||||
| Duration of intervention (min) | 101 (78–131) | 110 (100–160) | 86 (71–131) | 0.085 |
| Correct device performance | 29 (97) | 10 (91) | 19 (100) | 0.189 |
| Overall device success | 28 (91) | 10 (91) | 18 (95) | 0.691 |
| Valve model (Evolut-R/ Evolut-Pro/ Edwards) | 16 (53)/ 12 (40)/ 2 (7) | 5 (46)/ 4 (36)/ 2 (18) | 11 (58)/ 8 (42)/ 0 (0) | 0.366 |
| Clinical outcome | ||||
| Hospital length of stay (d) | 6 (5–8) | 5 (5–15) | 6 (5–7) | 0.931 |
| Complications at discharge | 10 (33) | 4 (36) | 6 (32) | 0.792 |
| New permanent pacemaker implantation | 6 (20) | 1 (9) | 5 (26) | 0.264 |
| Stroke and transient ischemic attack | 1 (3) | 1 (9) | 0 (0) | 0.189 |
| Acute kidney injury | 0 (0) | 0 (0) | 0 (0) | N/A |
| Bleeding | 5 (17) | 2 (18) | 3 (16) | 0.868 |
| Vascular complication | 2 (7) | 1 (9) | 1 (5) | 0.691 |
Data are presented as number (%) or median (interquartile range: 25%–75%).
BMI, body mass index; MMSE, mini mental state examination; N/A, not applicable; STS, Society of Thoracic Surgeons.
∗< 25% exercise load increase (post- vs pre-transcatheter aortic valve implantation).
Hemodynamic and tissue oximetric data at baseline and at the end of the exercise test, before and after TAVI
| Global | Baseline | At end of exercise test | |||||
|---|---|---|---|---|---|---|---|
| Pre-TAVI | Post-TAVI | Pre-TAVI | Post-TAVI | ||||
| HR (bpm) | 0.001 | 71 (65–76) | 71 (65–76) | 0.578 | 95 (78–104) | 94 (85–102) | 0.422 |
| MAP (mm Hg) | 0.038 | 94 (82–103) | 85 (78–92) | 0.023 | 111 (89–127) | 107 (94–116) | 0.405 |
| SpO2 (%) | 0.047 | 96 (96–98) | 98 (96–99) | 0.010 | 96 (94–97) | 99 (97–100) | 0.001 |
| RR (cpm) | 0.228 | 15 (12–21) | 14 (12–20) | 0.931 | 25 (22–28) | 23 (19–26) | 0.256 |
| SI (ml/m2) | < 0.001 | 33 (31–42) | 41 (37–46) | 0.006 | 47 (40–52) | 54 (43–63) | 0.032 |
| CI (l/min per m2) | < 0.001 | 2.5 (2.1–2.9) | 2.9 (2.5–3.2) | 0.009 | 4.5 (3.4–5.3) | 4.7 (3.4–6.4) | 0.019 |
| DO2I (ml/min per m2) | < 0.001 | 403 (357–500) | 501 (373–578) | 0.008 | 750 (564–902) | 816 (646–1073) | 0.008 |
| ctSO2 (%) | < 0.001 | 71 (66–76) | 68 (65–76) | 0.442 | 70 (65–72) | 74 (66–78) | 0.046 |
| mtSO2 (%) | 0.032 | 68 (61–70) | 63 (61–69) | 0.026 | 62 (58–65) | 71 (65–74) | < 0.001 |
Data are presented as median (interquartile range: 25%–75%).
bpm, beats per minute; CI, cardiac index; cpm, counts per minute; ctSO2, cerebral tissue oximetry; DO2I, indexed oxygen delivery; HR, heart rate; MAP, mean arterial pressure; mtSO2, muscular tissue oximetry; RR, respiratory rate; SI, stroke index; SpO2, pulsed oxygen saturation; TAVI, transcatheter aortic valve implantation.
Overall variation according to Friedman’s test.
Difference between medians according to Wilcoxon signed-rank test.
Figure 2Differences at the end of the exercise test between low- and high-responders after transcatheter aortic valve implantation (TAVI). (A) heart rate (HR); (B) mean arterial pressure (MAP); (c) respiratory rate (RR); (D) pulsed oxygen saturation (SpO2): (E) cerebral tissue oximetry (ctSO2); (F) muscular tissue oximetry (mtSO2); (G) stroke index (SI); (H) cardiac index (CI); (I) indexed oxygen delivery (DO2I). ∗ < 25% exercise load increase (post- vs pre-TAVI).